Skip to main content

Frontiers in Cancer Immunotherapy 2024

The Frontiers in Cancer Immunotherapy 2024 symposium aims to explore innovative therapies in cancer treatment amidst the rapidly evolving field of cancer immunotherapy. Despite notable successes, challenges persist in understanding the biology of certain tumor types and identifying targets for novel therapies. The symposium provides a platform for researchers, clinicians, and industry leaders to discuss progress, potential, and advancements in drug therapies and technologies for improved cancer treatment.

Sponsors

Presenting Partner

Cancer Discussion Group Lead Supporter


Bronze Sponsor

Merck

Academy Friends

The New Wave of AI in Healthcare

Rapidly evolving digital technologies are changing modern healthcare in unprecedented ways. Novel digital health solutions are embracing machine learning and artificial intelligence (AI) tools that empower patients and healthcare providers alike. However, given the speed of innovation, it can be challenging to stay abreast of the latest technological advances.

To showcase the latest advances in AI- and data-driven technologies in healthcare, the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai and the New York Academy of Sciences will convene multi-disciplinary scientists and clinicians working at the intersection of computer science and medicine for a 2-day, in-person symposium in New York City entitled “The New Wave of AI in Healthcare”.

This symposium will feature a keynote presentation by David C. Rhew, MD, Global Chief Medical Office and Vice President of Healthcare at Microsoft. In addition, leaders in the field will present plenary lectures, and there will be poster presentations by early career investigators, students, and postdocs. The New Wave of AI in Healthcare will provide a forum for the exchange of novel scientific research and expertise among multi-sector scientists and provide ample networking opportunities.

Presentation topics include:

  • Large-scale Foundation Models for Healthcare 
  • Next Generation Deep Learning for Healthcare 
  • High-Performance Computing 
  • Digital and Computational Pathology 
  • Digital Health 
  • AI Ethics in Healthcare 
  • Data Driven Research in Healthcare

Explorations in Consciousness: Death, Psychedelics, and Mystical Experience

Throughout the arc of history, humans have been fascinated with death, as well as mystical or peak experiences and other non-ordinary states of awareness — each with the potential to influence our understanding of the nature of consciousness. With recent advances in neuroscience and resuscitation medicine, millions of people have come close to, or even entered, what is now considered a gray zone of death by cardiopulmonary criteria, before being resuscitated back to life.

Near-death experiences (NDEs) have been reported throughout the world, often associated with long-term growth and psychological transformation. Occurring cross-culturally and since antiquity, these phenomena —along with the recent scientific investigation of psychedelic-occasioned mystical-type experience — often include an enhanced sense of personal meaning, purpose, existential and spiritual well-being.

What is consciousness?  Why are humans seemingly wired for these transcendent and meaning-making experiences?  What happens to consciousness upon physical death?  Are there common features in the variety of altered states of consciousness? This special one-day event features a notable group of international experts in consciousness research, neuroscience, psychedelics, mystical and near-death experience research, the history of comparative religion and mythology, along with a first-hand account of a near-death experience.

Ethical Considerations in Research for Pediatric Populations

There is an urgent need for new drugs and treatments to address a range of illnesses in infants, children, and adolescents, yet including these vulnerable populations in clinical research raises a number of ethical issues that are important to address. This event will explore key ethical considerations regarding the research participation of those who have not attained the legal age for consent to treatments or procedures involved in biomedical studies. Discussions will center on addressing consent, assent, and privacy in pediatric research, study design and regulatory issues, small sample size studies in genomics and rare disease research, health disparities, Covid-19 research in children, broad population-based disease prevention efforts, and will close with a look to the future of pediatric research.

Colloquium Conflict Management

The New York Academy of Sciences is a neutral convener of scientific symposia. We adhere to Accreditation Council for Continuing Medical Education (ACCME) principles for all of our programming. Please note that Johnson & Johnson is a sponsor of this convening, and The New York Academy of Sciences and NYU Grossman School of Medicine exercise full control over the planning of the program’s content, the selection of speakers and all enduring materials.

Vaccines for Respiratory Diseases

The symposium will focus on respiratory vaccine research and development, bringing together experts from various fields to discuss challenges and breakthroughs in vaccinology. Notably, it will cover the design of vaccines for respiratory diseases, including those targeting older adults and pregnant mothers and their infants, with updates ranging from preclinical research to surveillance and rollout.

Sponsors

Microbiology and Infectious Disease Discussion Group Lead Supporter

Silver Sponsor

Sickle Cell Disease: Existing Paradigms and Novel Approaches

Sickle cell disease (SCD) is a genetic blood disorder affecting approximately 6 million people worldwide, with an estimated 120 million individuals carrying the sickle cell trait.

Advances in scientific research are essential to developing improved treatments and enhancing the quality of life for those living with this condition.

The conference, “Sickle Cell Disease: Existing Paradigms and Novel Approaches,” will feature groundbreaking discussions and research across five pivotal topics:

  • Disparities, Real-world Challenges, Opportunity in Sickle Cell Disease
  • Modeling Sickle Cell Disease
  • Vascular Pathology in Sickle Cell Disease
  • Autologous Gene Editing and Reprogramming Cures — An Update
  • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Cures- Key Issues

This interdisciplinary symposium will unite leading clinicians, researchers, policymakers, and patient advocates from academia, regulatory bodies, and industry to foster information sharing and collaboration.

Sponsors

Presented By

The New York Academy of Sciences
Biochemical Pharmacology Discussion Group

Sponsored By

Lead Supporter: Biochemical Pharmacology Discussion Group

Bronze Sponsors

205th Annual Meeting of the New York Academy of Sciences

We invite our Members to join us at the 205th Annual Meeting of The New York Academy of Sciences. Academy Chair of the Board Jerry Hultin, with President and CEO Nicholas Dirks, will kick off the event with a welcome address and share updates about new Academy initiatives.

Cancer Metabolism and Signaling in the Tumor Microenvironment

April 17, 2024 | 8:30 AM – 5:25 PM ET

Scientists involved in basic, translational, and clinical cancer metabolism research are invited to attend a symposium hosted by the Academy in New York on April 17th. The event will focus on the intersection between cell signaling and metabolism in cancer. Topics include the intricate networks of metabolite-signaling in tumor progression, therapeutic targets, and translating findings into patient treatments. Plenary presentations, panel discussions, and networking opportunities will foster meaningful conversations among attendees and world-class speakers regarding tumor cell exploitation of cellular signaling and metabolic pathways for malignant growth.

Sponsor

Cancer Discussion Group Lead Supporter

What Near-Death and Psychedelic Experiences Reveal about Human Consciousness

A colorful illustration meant to depict something psychedelic.

A recent Academy event explored near-death experiences and the medical application of psychedelic remedies, combining elements of science and philosophy.

Published June 9, 2023

By David Freeman

What is the nature of consciousness? What happens to it at the brink of death—and beyond? In what ways can the scientific study of near-death experiences and the medicinal use of psychedelic compounds boost our understanding of the human condition and our ability to ease emotional suffering?

These and related questions were the focus of an Academy conference held on June 8, 2023, in New York City. The one-day event included presentations by psychologists, neurologists, biomedical researchers and a religious scholar. Additionally, there was a gripping first-person account of a near-death experience from renowned journalist and author Sebastian Junger.

What are Near-Death Experiences?

Near-death experiences, or NDE’s, are deeply affecting, often mystical episodes. Experts call them periods of “disconnected consciousness.” They affect some people who are close to death or in situations of grave physical or emotional danger. They are commonly marked by feelings of floating outside one’s body and the sensation of moving toward a bright light, as well with as encounters with dead relatives.

NDE’s have been documented across many different cultures and have been known since ancient times. “We’re talking about something that could be hundreds of thousands of years old,” said Brian C. Muraresku. He is the author of the 2020 book “The Immortality Key.” His book examines scientific evidence for the ritual use of psychedelics in classical antiquity. He was also one of the speakers at the conference.

There’s something about that kind of experience—near-death, psychedelic, mystical, whatever it is—that holds the entire human race together.

Brian C. Muraresku, author “The Immortality Key”

NDE’s are now known to be remarkably common. In recent research, 15 percent of intensive care unit patients reported having one. As did up to 23 percent of survivors of cardiac arrest. This is according to neuropsychologist Helena Cassol, Ph.D. Dr. Cassol is the scientific coordinator of Neurological Rehabilitation Center of the University Hospital of Liege in Belgium and also presented at the conference.

“More people have survived cardiac arrest and other situations and could recall those experiences” as a result of improved resuscitation techniques that have become available in recent years, she explained. She added that NDE’s now represent an emerging field of scientific research.

NDE’s can be personally transformative. Some people report a reduced fear of death in the wake of an NDE. Others report enhanced feelings of compassion or purpose. But some are saddled with a pattern of persistent intrusive thoughts or dreams or other negative after-effects. Given these possibilities, “I think it is important for people to be able to talk about these experiences and be heard in a nonjudgmental way,” Dr. Cassol said.

The Evolution of Near-Death Experiences

There may be an evolutionary basis for NDE’s. Daniel Kondziella, M.D., Ph.D., is a neurologist at Copenhagen University Hospital and an associate professor at the University of Copenhagen in Denmark. During his conference presnetation he described research linking the episodes to thanatosis. That’s the well-documented and remarkably consistent phenomenon in which animals—even insects—feign death in order to avoid being killed by predators.

The research suggests that the evolution of language in humans gave us the unique ability to transform this stereotyped behavior into the rich narratives used to describe the mysterious sensations and perceptions commonly seen in near-death experiences, Dr. Kondziella said. Not everyone is convinced by such research.

“Evolutionary explanations are just-so stories,” said Christof Koch, Ph.D. Dr. Koch is chief scientist and president of the Allen Institute for Brain Science, and also presented at the conference. “They may be true. They made be false. It just doesn’t matter. But the fact that we do have experiences—that is the remarkable thing.”

Studies of the neurological underpinnings of NDE’s suggest that the phenomenon arises amid a sort of blending of conscious states: waking, rapid-eye movement (REM) sleep and non-REM sleep.

“The physiological balance between conscious states is disrupted during the conditions of near-death, leading the brainstem arousal system controlling conscious states to blend waking and rapid eye movement consciousness into a hybrid state” known as REM intrusion,” said Kevin R. Nelson, M.D., a University of Kentucky neurologist and another speaker at the conference. “REM intrusion leads to many key features of near-death, including lying still, visual activation, out-of-body, and the experience’s narrative qualities.”

Most individuals who experience near-death are physiologically predisposed to REM intrusion, according to Dr. Nelson.

Psychedelics as Medical Treatment

As some scientists work to gain a better understanding of NDE’s, others are pursuing clinical trials of psychedelic compounds, which have been shown to trigger an altered state of awareness similar to that seen in people experiencing an NDE. A growing body of evidence suggests that these compounds—given under expert supervision and in carefully controlled settings—can ease emotional distress in terminally ill people quite profoundly.

One landmark 2016 study by researchers including Anthony P. Bossis, Ph.D., clinical assistant professor of psychiatry at NYU Grossman School of Medicine and another speaker at the conference, showed that a single treatment with psilocybin—a psychoactive compound found in some mushroom species that humans have consumed for thousands of years—brought rapid reductions in depression, anxiety, and hopelessness in people with terminal cancer.

The benefits of psilocybin treatment were greatest among individuals who reported strong mystical experiences during the sessions, according to Dr. Bossis. “The more robust that mystical experience, the greater the outcome in terms of reduction of depression,” he said. “These aren’t NDE’s,” he added, “but they’re deathlike experiences with a similar phenomenology.”

Recent research shows that psilocybin is just one of many drugs that can induce NDE-like such experiences and suggests that those induced by ketamine, an anesthetic with hallucinogenic effects, show greater similarity to NDE’s than those induced by psilocybin. But “we only studied the phenomenological similarity between subjective experiences” and didn’t assess the extent to which any of the drugs might be effective treatments for depression, said Charlotte Martial, Ph.D., a neuropsychologist at the University of Liege in Belgium and another conference speaker.

Junger’s Brush with Death

Sebastian Junger’s brush with death came three years ago, following the rupture of an aneurysm in his pancreatic artery. As doctors rushed to stanch the bleeding that threatened his survival, he recalled, he encountered an “infinitely dark” pit that threatened to pull him in but also the welcoming “essence” of his beloved, long-dead father. “It wasn’t quite a vision. It was halfway between a vision and a feeling,” he said.

A self-described atheist whose father was a physicist, Junger said the experience nonetheless led him to reconsider his ideas not only about life and death but about the nature of the universe.

“I wish I could say I believe in an afterlife. I don’t. But I definitely have lost the certitude of my rationality,” he said, adding that he now believes it was possible that “some kind of energy or quantum phenomena” interacts with reality in ways we don’t understand.

If some see NDE’s as possible evidence of the supernatural or a phenomenon beyond the scope of scientific knowledge, others are convinced that they are simply the result of physiological processes—such as the oxygen starvation to the brain that can result from cardiac arrest.

There is a “perfectly natural explanation for NDE’s,” said Dr. Kondziella. “No need to postulate any supernatural events.”

But Raymond A. Moody, Jr., M.D., Ph.D., the keynote speaker whose remarks set the stage for the conference, expressed uncertainty over what near-death experiences actually represent.

Science? Or philosophy?

“I really just don’t know,” he said. “I think the questions that we are dealing with—a lot of them are not yet scientific questions,” he added. “They are philosophical questions.”

Dr. Moody is the author of the 1975 book “Life after Life” that sparked interest in near-death experiences. He has been documenting NDE’s for many years and is credited with coining the term near-death experience.

Uncertainty about life’s transcendent questions is inevitable, according to Karen Armstrong, a London-based author of numerous books on religious affairs and the other keynote speaker at the conference.

“Neither religion nor science can really respond. Ultimately, we are all in a ‘Cloud of Unknowing,’” she said in a reference to an anonymous 14th Century text on spirituality and Christian mysticism. “We are all just trying to find some meaning in it all,” she added, “without which we humans fall very easily into despair.”

For Brian C. Muraresku, the strange perceptions and complex emotions seen in near-death and similar visionary experiences are central to the human experience. “There’s something about that kind of experience—near-death, psychedelic, mystical, whatever it is—that holds the entire human race together.”

Also read: Music on the Mind: A Neurologist’s Take

Collaboration is Key for 2023 Ross Prize Awardees

Two researchers stand at podiums and address a crowd.

Ask Helen Hobbs, M.D. and Jonathan Cohen, Ph.D. about the secret of their research success, and it will come down to one core element: their partnership.

Published May 31, 2023

By David Freeman

The pair were recently awarded the 2023 Ross Prize in Molecular Medicine by the Feinstein Institutes for Medical Research and the journal Molecular Medicine for their pioneering and collaborative work in defining the genetic risk factors for dyslipidemias and metabolic liver disease that have led to the rational design of new therapies.

Hobbs trained as a physician and a human geneticist, while Cohen trained as a bench scientist and a physiologist. But they also recognize how the different perspectives they bring to their work contributes to its success.

“Helen’s got a very good feel for the big picture in terms of the scientific direction pathway areas to choose and which observations we should follow up…she is far more selectively curious than I am,” says Cohen of their research styles, “(while) I tend to pay attention to experimental details.”

Their complementary differences can also be seen in their personalities, “Helen is ‘s very exuberant and very extroverted, and I tend to be more introverted and certainly more self-contained,” says Cohen.

Hobbs adds, “Jonathan is very easy to work with… he’s got a very level disposition. We both need each other to balance each other out.”

In addition to their strengths both also cite good mentors as pivotal guides in their careers.

“A lot of people want to look for a lab that’s doing the latest technique or, you know, papers in Science and Nature,” says Cohen, “I think having somebody who’s a good first-rate mentor is a number one priority.”

Where it All Started

Cohen was fortunate to connect to Weiland Gevers, chair of biochemistry at the University of Cape Town in South Africa while he was still in high school. A similar relationship with Scott Grundy, head of the Center of Human Nutrition at the University of Texas Southwestern Medical Center, made it possible for Cohen to relocate to Dallas.

There, he soon would meet Hobbs, who moved to UT Southwestern in 1983. A trained physician, she was encouraged by Donald Selden, M.D., head of internal medicine at UT Southwestern to join Nobel Laureates Michael S. Brown and Joseph L Goldstein’s lab whose work in the regulation of cholesterol metabolism, laid the foundation for Hobbs’ own study of the genes that caused severe hypercholesterolemia.

In 1999 Hobbs was asked to help design an epidemiological study for a large grant that scaled from genes to populations. She knew she needed the right partner if she was going to take on the challenge.

“I was used to working with families, not populations,” recalls Hobbs. “I knew immediately if I was going to do this, … that I really needed a partner who had more quantitative skills than I did.”

She started talking to Cohen, and in just six weeks they launched the foundation for the Dallas Heart Study, a large multi-ethnic population study.

“We spent nights up in our labs writing this study, talking to each other, thinking about it, and getting advice from epidemiologists.”

Looking at Gene Variations

While most researchers in the field at the time were operating under the assumption that gene variations found frequently in the population were the cause of common diseases (like hypertension), Cohen and Hobbs took a different approach – they looked for gene variations that were rare but were more likely to cause disease if a person had that variant.

The multi-ethnic nature of the Dallas Heart Study, made up of 50% African-Americans, the most genetically diverse population in Dallas, and including Hispanic and European participants, led them to quickly zero in on mutations in a gene called PCSK9 that were associated with reduced plasma levels of low-density lipoprotein (LDL) cholesterol and decreased risk of heart disease.

This revolutionary discovery meant that new drug development could be targeted at PCSK9 to lower cholesterol levels in patients, and two therapies have since been FDA-approved to do just that. Despite the opportunities such a discovery could yield, the pair are more focused on how their work solves problems, rather than profiting from their foundational work.

“I am really thinking about solving a problem in a lab and answering a question, and the thrill I get is in getting that answer,” says Hobbs.

Doing What They Love

Ultimately, the two are happy to be in a lab doing what they love.

“I like the whole package of being an academic scientist,” says Hobbs. “I love the research, and I like the teaching, the mentoring. There’s just so many aspects of our job that I enjoy, and I just didn’t want to be distracted from them.”

Cohen can’t picture himself as anything other than a scientist, “I can’t imagine…doing anything other than what I do.”

Today, The Hobbs-Cohen Lab continues to use human genetics to identify new therapeutic targets to treat cardiovascular and metabolic disorders and to define key pathways in lipid metabolism. More recently, they discovered the first genetic cause of fatty liver disease in humans. They also continue to employ their dynamic partnership in the way they run their lab.

“There’s always somebody in the lab for the students and post-doctoral fellows to talk with. I think that if you were to talk to the people in our lab, they would see this as a very good thing,” says Hobbs. “But one thing’s always true. Nobody can split us.”

“To have our work recognized by such an honor (as the Ross Prize) is incredibly gratifying, especially for us to be honored together…there’s just no way any of it could have been done without the other,” said Hobbs.

Cohen agrees. “I was just going to say the same thing.”


Read more about the Ross Prize and past awardees: